Advanced Search
Menten AI

Menten AI

A company using quantum computing and machine learning to design proteins.

Menten Biotechnology Labs - also known as Menten AI - is a company that develops new protein therapeutics for drug development through the use of machine learning and quantum computing. It was founded in 2018 by Hans Melo, Vikram Mulligan, and Tamas Gorbe. Menten Biotechnology Labs is headquartered in San Francisco, California, United States. It has received funding from investors such as Uncork Capital, Founders X, and Khosla Ventures. Menten Biotechnology was a cohort of Y Combinator's W20.


Menten Biotechnology Labs leverages machine learning (in the form of Rosetta) and quantum computing (in the form of D-Wave) capabilities to design and modify proteins. These newly generated proteins are meant to be used for drug development purposes, though it can also be used for manufacturing processes. The company's approach is meant to address the current approach, where new protein structures are generated through random trials instead of intentional designs.


June 2020
Menten AI raises a $3,700,000 seed round from FoundersX Ventures, Khosla Ventures, Social Impact Capital and Uncork Capital.
December 2019
Menten AI raises a $355,000 seed round from Creative Destruction Lab and Y Combinator.

Funding rounds


Further reading

Documentaries, videos and podcasts



Greg Kumparak
March 17, 2020
With YC's W20 Demo Day coming in at nearly 200 companies, we've decided to split our recap into multiple posts for easier reading. These are the hardware, AI/ML, and developer-focused companies


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.